Share This Page
Drugs in ATC Class V04CG
✉ Email this page to a colleague
Drugs in ATC Class: V04CG - Tests for gastric secretion
| Tradename | Generic Name |
|---|---|
| HISTALOG | betazole hydrochloride |
| HISTAMINE PHOSPHATE | histamine phosphate |
| PEPTAVLON | pentagastrin |
| >Tradename | >Generic Name |
Patent and market landscape for ATC V04CG (tests for gastric secretion): what expires, what’s protected, and where generics and competitors face barriers
ATC V04CG covers diagnostic tests for gastric secretion. In practice, the category’s competitive dynamics cluster around radioisotope and non-radioisotope gastric function testing (classically including gastric emptying and acid secretion assessment), plus test kits and branded diagnostic reagents used in clinical workflows. The patent estate in this space is typically fragmented: device/workflow IP, formulation or kit chemistry, and use patents tied to specific labeling, dosing, or patient-selection criteria.
A full, decision-grade patent map requires tying the ATC umbrella to specific FDA/EMA/Nationally-authorized products, kit configurations, active ingredients, and indications and then extracting: Orange Book (if applicable), national registers, and patent litigation/settlements. Under the constraints for completeness, no such product-to-patent mapping can be produced from the provided prompt alone.
Which products sit under ATC code V04CG tests for gastric secretion?
Featured-snippet answer: ATC V04CG is a diagnostic category, not a single drug substance, so market and IP sit by specific gastric-function testing products and kits, not by one universal active ingredient.
Typical sub-markets that drive V04CG activity
- Diagnostic kits/reagents for measuring gastric secretion or related gastric function endpoints (method-dependent).
- Nuclear medicine-based tests that use radiolabeled tracers and associated preparation workflows (where available in the relevant jurisdiction).
- Non-invasive gastric function tests using patient dosing protocols and analytical readouts (where branded kits exist).
Why the “ATC-only” view breaks patent mapping
Patent claims are normally directed to:
- A specific composition (kit formulation).
- A specific method (administration and measurement steps).
- A specific use (indication, patient population, or diagnostic interpretation).
- A specific component (e.g., specialized reagent, calibration/control system).
Without the named products, a patent estate count, expiration schedule, and infringement-risk profile cannot be stated accurately.
What patents protect gastric secretion tests (V04CG): composition, method-of-use, or device workflow?
Featured-snippet answer: All three commonly show up, but which dominates depends on whether the product is a kit, a test protocol, or a radiopharmaceutical workflow.
Composition and kit protection
Where the product is a kit, patents often cover:
- Reagent chemistry and stabilization.
- Specific concentration ranges and buffer systems.
- Packaging and shelf-life enabling components.
Method-of-use and patient protocol patents
Method claims can cover:
- The dosing regimen and timing.
- The measurement steps and analytic logic.
- Diagnostic thresholds tied to an endpoint.
Process and manufacturing patents
For any commercial reagent, process IP can cover:
- Synthesis and purification of key intermediates.
- Sterility/aseptic workflows (for sterile components).
- Control assays and release testing.
Device-adjacent workflow protection
If the test depends on proprietary instrumentation, IP can include:
- System-level calibration methods.
- Software interpretation rules.
- Consumable integration.
When does exclusivity end for gastric secretion tests under V04CG?
Featured-snippet answer: Exclusivity end dates depend on the specific marketed product and its regulatory exclusivity framework, including patent term, and where relevant, regulatory exclusivity (and any pediatric extensions) tied to that product’s FDA/EMA authorization.
A category-level exclusivity timeline for ATC V04CG cannot be produced without identifying the underlying product(s) and their regulatory reference dates.
What are the Orange Book status and patent listings for V04CG gastric secretion tests?
Featured-snippet answer: Orange Book applies to FDA-approved drugs with listed patents. Many diagnostic products used in gastric testing are not centrally tracked as drug submissions in a way that maps cleanly to ATC categories, and many are devices/diagnostics or radiopharmaceuticals whose listing patterns differ.
A precise Orange Book status requires:
- The exact FDA product names (brand/generic),
- Their NDA/BLA reference (if any),
- Their listed patents and expiration dates.
No such product-level inputs are present.
Which companies dominate V04CG gastric secretion testing, and where are the patent chokepoints?
Featured-snippet answer: Dominance is product-dependent, and patent chokepoints usually sit where a branded kit or protocol is hard to replicate due to composition constraints or method claim sensitivity.
Without the specific V04CG products:
- company market shares cannot be quantified,
- the relevant assignee landscape cannot be enumerated,
- and chokepoints cannot be validated.
How strong is the patent estate for gastric secretion tests: counting active patents by jurisdiction and claim type
Featured-snippet answer: Patent strength in this space is strongest where claims cover both the kit composition and the tested method, forcing a generic competitor into a design-around on multiple axes.
A quantified estate strength measure needs:
- patent families by jurisdiction,
- active claim scope,
- remaining life,
- and known litigation or regulatory challenges.
None of those are available from the ATC code alone.
What patent litigation affects competitors in gastric secretion tests (V04CG)?
Featured-snippet answer: Litigation risk typically rises when a branded product has listed patents tied to method-of-use and when generic competitors use substantially similar protocols.
A credible litigation map requires:
- case captions,
- forum,
- asserted patents,
- and outcomes/settlements.
No litigation dataset is provided.
What generic entry risks exist for V04CG tests: Paragraph IV, design-around, or biosimilar-style risk?
Featured-snippet answer: Paragraph IV risk exists only if the product is eligible for the Hatch-Waxman pathway with Orange Book patents. Many gastric secretion tests are not typical Hatch-Waxman small-molecule/generic frameworks, so the risk is often design-around rather than an Orange Book Paragraph IV.
Paragraph IV scenarios (only if FDA drug + Orange Book patents apply)
- A generic kit or formulation seeking approval that relies on proving non-infringement or invalidity of listed patents.
- Settlement agreements can lock out commercial entry by a set date.
Design-around scenarios
- Competitors change timing, dosing, reagent composition, or analytical interpretation to avoid method claims.
- They may rely on alternative validated protocols that do not infringe.
Biosimilar-style risk
Biosimilars generally do not apply unless the product is a biological reference product. Diagnostic gastric secretion tests are not automatically biosimilar territory without product identity.
How do gastric secretion tests compare with other gastric-function diagnostics in patent strategy (V04CG vs adjacent ATC categories)?
Featured-snippet answer: Adjacent gastric-function categories show similar IP patterns, but the mix shifts toward:
- radiopharmaceutical-specific workflows in some subclasses,
- kit formulation in others,
- and protocol interpretation where diagnostic readouts are standardized.
A comparative patent strategy requires actual products from V04CG and comparison ATCs to ground the claim-coverage discussion.
Regulatory pathway implications: FDA vs EMA vs national authorizations for gastric secretion tests
Featured-snippet answer: Regulatory pathway affects what IP gets listed and how exclusivity is granted, which in turn determines the likely contest model (Paragraph IV vs device/diagnostic competition vs design-around).
Because V04CG category mapping to specific regulatory products is not provided, pathway-specific exclusivity and IP listing patterns cannot be stated.
Key Takeaways
- ATC V04CG is an IP-mapped category only through specific marketed test products and kits, not as a single patent estate.
- The patent landscape in gastric secretion testing is usually a mix of composition/kit, method-of-use, manufacturing, and workflow IP.
- Exclusivity, Orange Book status, and litigation risk are product-specific and cannot be computed from the ATC code alone.
- Competitive entry risk is often driven by design-around feasibility rather than Paragraph IV unless the underlying product is an FDA drug with Orange Book-listed patents.
FAQs
- Which claim types most often block substitutes for gastric secretion diagnostic kits?
- How do settlements typically affect entry dates for diagnostic products with listed patents?
- What manufacturing and stability IP matters most for reagent-based gastric secretion tests?
- When does a gastric secretion diagnostic move from kit IP to protocol IP in litigation risk?
- How do radiolabeled gastric secretion tests change the competitive and IP landscape versus non-radioisotope kits?
References
- ATC/DDD Index (classification for ATC V04CG).
More… ↓
